1 Targeted drugs have successfully tackled this issue and facilitated cancer-predominant therapy with a superior safety profile (e.g.trastuzumab for HER2 + breast cancer, 2 crizotinib for EML4-ALK + lung cancer, 3 imatinib for BCR-ABL + leukaemia 4 ).